|
ISRCTN
|
ISRCTN53268296
|
|
ClinicalTrials.gov identifier
|
|
|
Public title
|
Low dose inhaled nitric oxide in patients with acute lung injury
|
|
Scientific title
|
Low dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial
|
|
Acronym
|
N/A
|
|
Serial number at source
|
INOT06
|
|
Study hypothesis
|
To evaluate the clinical efficacy of low-dose (5-ppm) inhaled nitric oxide in patients with acute lung injury.
|
|
Lay summary
|
Background and study aims
Acute respiratory distress syndrome (ARDS) is a disease in which the lungs are inflamed, wet and there is difficulty transmitting oxygen from the air that enters the lung as part of the breathing process into the blood. It has many causes including infectious and non-infectious. The objectives of this study were to add a gas called nitric oxide(NO) to the air that participants were breathing in order to raise the oxygen level in the blood in hopes of improving outcome in participants with ARDS.
Who can participate?
Patients aged 18 and over, regardless of sex, who have ARDS and are on a breathing machine (called a ventilator) in order to enable oxygen transfer into the blood.
What does the study involve?
The study compared inhaled nitric oxide (INO) added to the air the patient was breathing though the machine with a placebo nitrogen, a safe gas that makes up most of the air that we breathe and would have no effect on ARDS. All participants will receive the same treatment that they would have received for ARDS, even if they had not participated in the study. If patients were randomly allocated to the group receiving inhaled nitric oxide, this would have been the additional therapy.
What are the possible benefits and risks of participating?
By participating it is possible that the subject will have improved oxygenation and that this may lead to improved outcome. There are no anticipated potential side effects of the treatment when delivered at the doses that will be used in this study.
Where is the study run from?
There were 35 centers taking part in this trial and the lead center is St. Johns Mercy Hospital St. Louis, Missouri.
When is study starting and how long is it expected to run for?
The start date of the study was 1996 and the duration of the study was approximately 3 years. Recruitment of participants was until late summer/fall 1999.
Who is funding the study?
The study was funded by INO Therapeutics (Now called IKARIA). They paid the costs associated with the trial.
Who is the main contact?
Phil Dellinger
dellinger-phil@cooperhealth.edu
|
|
Ethics approval
|
Human Subjects Committee (USA), 15 February 1996
|
|
Study design
|
Multicenter randomized blinded placebo-controlled
|
|
Countries of recruitment
|
United States of America
|
|
Disease/condition/study domain
|
Acute lung injury
|
|
Participants - inclusion criteria
|
1. Mechanically ventilated patients with acute lung injury
2. Ratio of partial pressure of arterial oxygen (O2) to the fraction of inspired partial pressure of oxygen in arterial blood/fraction of inspired oxygen (Pa02/FiO2) ratio of 250 or less
|
|
Participants - exclusion criteria
|
Sepsis as the cause of the acute lung injury
|
|
Anticipated start date
|
27/03/1996
|
|
Anticipated end date
|
08/09/1999
|
|
Status of trial
|
Completed |
|
Patient information material
|
Not available in web format, please use the contact details below to request a patient information sheet
|
|
Target number of participants
|
385
|
|
Interventions
|
Inhaled nitric oxide (5ppm) or placebo (nitrogen gas) is delivered with mechanical ventilator breaths until the patient is extubated or for a total of 28 days.
|
|
Primary outcome measure(s)
|
Days alive and off mechanical ventilation
|
|
Secondary outcome measure(s)
|
Pulmonary function including spirometry, lung volumes and diffusion of carbon monoxide evaluated at 6 months
|
|
Sources of funding
|
Ohmeda PPD/INO Therapeutics Inc. (USA)
|
|
Trial website
|
|
|
Publications
|
2004 results in http://www.ncbi.nlm.nih.gov/pubmed/15069048
|
|
Contact name
|
Dr
Richard
Dellinger
|
|
Address
|
Cooper University Hospital
One Cooper Plaza
|
|
City/town
|
Camden, New Jersey
|
|
Zip/Postcode
|
19102
|
|
Country
|
United States of America
|
|
Tel
|
+1 856 342 2632
|
|
Fax
|
+1 856 968 8306
|
|
Email
|
dellinger-phil@cooperhealth.edu
|
|
Sponsor
|
Ohmeda/INO Therapeutics Inc (USA)
|
|
Address
|
c/o Ikaria Inc
Perryville III Corporate Park
53 Frontage Road
|
|
City/town
|
Hampton, New Jersey
|
|
Zip/Postcode
|
08827
|
|
Country
|
United States of America
|
|
Sponsor website:
|
http://www.ikaria.com
|
|
Date applied
|
18/11/2011
|
|
Last edited
|
31/01/2012
|
|
Date ISRCTN assigned
|
31/01/2012
|
